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1. Introduction
Diabetic ketoacidosis (DKA), the most common endocrinal emergency remains a life-threat‐
ening condition despite improvements in diabetes care [1]. The mortality and morbidity
rates remain high worldwide, especially in developing countries and among non-hospital‐
ized patients [2,3], which highlight the importance of early diagnosis and implementation of
effective preventive and management strategies. The adage "The child is not a miniature
adult" is most appropriate when considering DKA. The fundamental pathophysiology of
DKA is the same in children as in adults; however, the child differs from the adult in a num‐
ber of characteristics which raise some important considerations in management [2].
The purpose of this chapter is to briefly review the pathophysiology of DKA and discuss
recommended treatment protocols and current standards of care pertaining to children, ado‐
lescents and adults with type 1 or 2 diabetes presenting with DKA. The information provid‐
ed is based on evidence from published studies and internationally accepted guidelines
whenever possible and, when not, supported by expert opinion or consensus [1-5]. Current
concepts of cerebral edema, recommendations and strategies for the prediction and preven‐
tion of DKA and hence its complications are finally presented.
The considerations and recommendations included are in agreement with those endorsed
by the American Diabetes Association (ADA), Lawson Wilkins Pediatric Endocrine Society
(LWPES), European Society for Pediatric Endocrinology (ESPE), and the International Soci‐
ety for Pediatric and Adolescent Diabetes (ISPAD) [2-5]. Thus, this book chapter will pro‐
vide easy and practical information to guide healthcare professional who manage DKA in
all age groups.
© 2013 Abdelghaffar; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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2. Definition of Diabetic Ketoacidosis (DKA)
The biochemical criteria for DKA include the following triad [4]:
• Hyperglycemia (blood glucose >11 mmol/L [200 mg/dL])
• Venous pH <7.3 and/or bicarbonate <15 mmol/L
• Ketonemia and ketonuria
3. Pathophysiology of DKA
Diabetic ketoacidosis (DKA) results from absolute or relative deficiency of circulating insu‐
lin and the combined effects of increased levels of the counterregulatory hormones: cate‐
cholamines, glucagon, cortisol and growth hormone [5].
Absolute insulin deficiency occurs in the following conditions:
• undiagnosed type 1 diabetes mellitus (T1DM); DKA is reported be the first presentation
in about 25% of cases especially in those less than 5 years old [ 2 ].
• patients on treatment who miss their insulin doses, especially the long-acting component
of a basal-bolus regimen. It is estimated that 75% of DKA episodes are associated with in‐
sulin omission or treatment error [6].
• patients who use insulin pump if insulin delivery fails [7].
Relative insulin deficiency, on the other hand, occurs when the concentrations of counterregu‐
latory hormones increase in response to stress in conditions such as:
• sepsis,
• trauma, or
• gastrointestinal illness with diarrhea and vomiting.
The combination of low serum insulin and high counterregulatory hormone concentrations
results in an accelerated catabolic state with increased glucose production by the liver and
kidney (via glycogenolysis and gluconeogenesis), impaired peripheral glucose utilization re‐
sulting in hyperglycemia and hyperosmolality, and increased lipolysis and ketogenesis,
causing ketonemia and metabolic acidosis [4].
Hyperglycemia and hyperketonemia cause osmotic diuresis, dehydration, and electrolyte
loss. This stimulates stress hormone production, which induces insulin resistance and leads
to a vicious circle, worsening the hyperglycemia and hyperketonemia. Fatal dehydration
and metabolic acidosis will ensue if management is not initiated. Poor tissue perfusion or
sepsis may lead to lactic acidosis which can aggravate the ketoacidosis [5].
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At presentation, the magnitude of specific deficits of fluid and electrolytes in an individual
patient varies depending upon the extent to which the patient was able to maintain intake of
fluid and electrolytes, and the content of food and fluids consumed before coming to medi‐
cal attention and the duration and severity of illness [8].
4. Epidemiology of DKA
There is wide geographic variation in the frequency of DKA at onset of diabetes; rates inver‐
sely correlate with the regional incidence of type 1 diabetes. Frequencies range from 15 to
70% in different regions of the world [9 -14].
4.1. Frequency of DKA
At disease onset
DKA at diagnosis of type 1 diabetes occurs more commonly in [15,16]:
• children younger than four years of age
• children with absent first-degree relative with T1DM and
• families of a lower socioeconomic class
Type 2 diabetes mellitus (T2DM), associated with increased rates and severity of obesity,
may account for as much as one half of newly diagnosed diabetes in those aged 10 to 21
years, depending on the socioeconomic and ethnic composition of the population [2]. Acute
decompensation with DKA has been recognized to occur at the time of diagnosis in as many
as 25% of children with type 2Diabetes Mellitus (T2DM0 [17].
In children with established diabetes (recurrent DKA)[4]
The risk of DKA in established T1DM is 1–10% per patient per year
Risk is increased in the following conditions [18 ]:
• poor metabolic control or previous episodes of DKA
• peripubertal and adolescent girls
• psychiatric disorders, including those with eating disorders
• difficult or unstable family circumstances
• omission of insulin
• limited access to medical services
• insulin pump therapy
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4.2. Diagnosis of DKA
Although DKA is defined by the biochemical triad of ketonemia, hyperglycemia and acide‐
mia, several exceptions do exist which may provide a diagnostic dilemma for the physician
in the emergency room. Examples of such are:
• "Euglycemic ketoacidosis’’: Partially treated children and children who have consumed
little or no carbohydrate may present rarely with mildly increased blood glucose concen‐
trations [19].
• Absent or mild metabolic acidosis, ketonemia and ketonuria: This may occur in the Hy‐
perglycemic Hyperosmolar State (HHS) or if the patient experiences severe vomiting
which may lead to alkalosis which can mask the present acidosis.
• Hyperglycemic hyperosmolar state (HHS), also referred to as hyperosmolar nonketotic
coma, may occur in young patients withT2DM, but rarely in T1DM subjects. The criteria
for HHS include [20-22]:
◦ plasma glucose concentration >33.3 mmol/L (600 mg/dL)
◦ arterial pH >7.30
◦ serum bicarbonate >15 mmol/L
◦ small ketonuria, absent to mild ketonemia
◦ effective serum osmolality >320 mOsm/kg
◦ stupor or coma
It is important to recognize that overlap between the characteristic features of HHS and
DKA may occur. Some patients with HHS, especially when there is very severe dehydration,
have mild or moderate acidosis. Conversely, some children with T1DM may have features
of HHS (severe hyperglycemia) if high carbohydrate containing beverages have been used
to quench thirst and replace urinary losses prior to diagnosis [22].
• Other diagnostic difficulties may be faced in the very young age such as the following [2]:
◦ Polyuria, polydipsia and weight loss which are characteristic features of diabetes are
difficult to demonstrate in the very young.
◦ up to 70% of the young have DKA as a first presentation, hence, at presentation, dura‐
tion of DKA is usually longer, dehydration and acidosis are more severe, as young chil‐
dren have relatively higher basal metabolic rate, and a relatively large surface area
relative to body mass.
• Measurement of blood ß-hydroxybutyrate (ß -OHB) concentration, may not be available
in all labs, besides, urine Ketone testing can be misleading due the following reasons [2,4]:
◦ The used method does not detect the major ketone body B-hydroxybutyrate. (sodium
nitroprusside only measures acetoacetate and acetone). Serum ß-OHB concentrations,
Type 1 Diabetes296
may be increased to levels consistent with DKA when a urine ketone test is negative or
shows only trace or small ketonuria
◦ The readings are qualitative depending on color comparisons
◦ High doses of Vitamin C may cause false-negative results, while some drugs may, on
the other hand, give false-positive results.
5. Management of DKA
5.1. Goals of therapy
Management of DKA should be mainly directed to correction of acidosis. Immediate aims of
management include [1,4]:
• Expansion of the intravascular volume
• Correction of deficit in fluids, electrolyte & acid base status
• Initiation of Insulin therapy
• Assessment and monitoring of therapy
5.2. Place of management
The child with DKA should receive care in a unit that has:
• Experienced nursing staff trained in DKA management
• Written guidelines for DKA management
• Access to laboratories that can provide frequent and timely measurements of biochemical
variables
• A specialist/consultant pediatrician experienced in the management of DKA should su‐
pervise inpatient management [4].
Children with severe DKA or those at high risk for cerebral edema should be treated in an
intensive care unit (pediatric, if available) or in a unit that has equivalent resources and su‐
pervision, such as a children’s ward specializing in diabetes care [4].
In a child with established diabetes, whose parents have been trained in sick day manage‐
ment, and who presents with mild DKA, can be managed in an outpatient health care facili‐
ty (e.g., emergency ward), provided an experienced diabetes team supervises the care [15].
Emergency Assessment [23]
• Clinically evaluate the patient to confirm the diagnosis and determine its cause. Carefully
look for evidence of infection.
• Assess level of consciousness
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• Weigh the patient.
• Assess clinical severity of dehydration. Signs of dehydration include dry mucus mem‐
branes, sunken eyes, absent tears, weak pulses, and cool extremities. The three most use‐
ful individual signs for assessing dehydration in young children and predicting at least
5% dehydration and acidosis are:
◦ prolonged capillary refill time (normal capillary refill is < 1.5-2 seconds)
◦ abnormal skin turgor (’tenting’ or inelastic skin)
◦ hyperpnea
• .≥10% dehydration is suggested by the presence of weak or impalpable peripheral pulses,
hypotension, and oliguria.
Biochemical assessment [1,4]
• Obtain a blood sample for laboratory measurement of serum or plasma glucose, electro‐
lytes, bicarbonate, blood urea nitrogen, creatinine, osmolality, venous (or arterial in criti‐
cally ill patient) pH, partial pressure of Carbon dioxide( pCO2), calcium, phosphorus, and
magnesium concentrations (if possible), Glycosylated Hemoglobin (HbA1c), hemoglobin
and hematocrit or complete blood count.
◦ Increased serum urea nitrogen and hematocrit may be useful markers of the severity of
extracellular fluid (ECF) contraction.
◦ It has to be noted that an elevated white blood cell count in response to stress is charac‐
teristic of DKA and is not necessarily indicative of infection [24].
◦ Metabolic acidosis being an important landmark of DKA is also helpful to grade the se‐
verity of the condition and hence the prognosis by assessing its degree as follows [15]:
• Mild DKA: venous pH <7.3 or bicarbonate <15 mmol/L
• Moderate DKA: pH <7.2, bicarbonate <10 mmol/L
• Severe DKA: pH <7.1, bicarbonate <5 mmol/L
• Perform a urinalysis for ketones.
• Measurement of blood ß-OHB concentration, if available, is useful to confirm ketoacidosis
and may be used to monitor the response to treatment [25].
• Obtain appropriate specimens for culture (blood, urine, throat), if there is evidence of in‐
fection.
• If laboratory measurement of serum potassium is delayed, perform an electrocardiogram
(ECG) for baseline evaluation of potassium status.
Supportive measures [1]:
• Secure the airway and empty the stomach by continuous nasogastric suction to prevent
pulmonary aspiration, in case there is deterioration in conscious level.
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• A peripheral intravenous (IV) catheter should be placed for convenient and painless re‐
petitive blood sampling. An arterial catheter may be necessary in some critically ill pa‐
tients managed in an intensive care unit.
• Perform continuous electrocardiographic monitoring to assess T-waves for evidence of
hyper- or hypokalemia
• Give oxygen to patients with severe circulatory impairment or shock
• Give antibiotics to febrile patients after obtaining appropriate cultures of body fluids
• Catheterize the bladder if the child is unconscious or unable to void on demand (e.g., in‐
fants and very ill young children)
6. Further clinical and biochemical monitoring
Meticulous monitoring of the patient’s clinical and biochemical response to treatment is
mandatory for timely adjustments in treatment as indicated by the patient’s clinical or labo‐
ratory data. Documentation on a flow chart of hour-by-hour clinical observations, IV and or‐
al medications, fluids, and laboratory results is very helpful.
Monitoring should include the following [4]:
• Hourly (or more frequently as indicated) vital signs (heart rate, respiratory rate, blood
pressure)
• Hourly (or more frequently as indicated) neurological observations for warning signs and
symptoms of cerebral edema. The latter include:
◦ Headache
◦ recurrence of vomiting
◦ change in neurological status (restlessness, irritability, increased drowsiness, inconti‐
nence) or specific neurologic signs (e.g., cranial nerve palsies, abnormal pupillary re‐
sponses)
◦ inappropriate slowing of heart rate
◦ rising blood pressure
◦ decreased oxygen saturation
• Amount of administered insulin
• Hourly (or more frequently as indicated) accurate fluid input (including all oral fluid) and
output.
• Capillary blood glucose should be measured hourly (but must be cross-checked against
laboratory venous glucose, as capillary methods may be inaccurate in the presence of
poor peripheral circulation and acidosis).
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6.1. Laboratory tests
• Serum electrolytes, glucose, blood urea nitrogen, hematocrit and blood gases should be
repeated 2-hourly for the first 12 hours, or more frequently, as clinically indicated, in
more severe cases.
• Urine ketones until cleared or blood ß-OHB concentrations, if available, every 2 hours
• If the laboratory cannot provide timely results, a portable biochemical analyzer that meas‐
ures plasma glucose, serum electrolytes and blood ketones on fingerstick blood samples
at the bedside is a useful adjunct to laboratory-based determinations [2].
• Additional calculations that may be informative:
◦ Anion gap = serum sodium(Na) – {serum chloride (Cl) + serum bicarbonate (HCO3)} :
normal is 12 ± 2 (mmol/L). In DKA, the anion gap is typically 20–30 mmol/L; an anion
gap >35 mmol/L suggests concomitant lactic acidosis.
◦ Corrected sodium = measured Na + 2([plasma glucose -5.6]/5.6) (mmol/L) The meas‐
ured serum sodium concentration is an unreliable index of the degree of ECF contrac‐
tion as glucose, largely restricted to the extracellular space, causes osmotic movement
of water into the extracellular space thereby causing dilutional hyponatremia.
◦ Therefore, it is important to calculate the corrected sodium (using the above formula)
and monitor its changes throughout the course of therapy. As the plasma glucose con‐
centration decreases after administering fluid and insulin, the measured serum sodium
concentration should increase (positive sodium load), but it is important to appreciate
that this does not indicate a worsening of the hypertonic state. A failure of measured
serum sodium levels to rise or a further decline in serum sodium levels with therapy is
thought to be a potentially ominous sign of impending cerebral edema
◦ Effective osmolality (mOsm/kg)= 2x(Na + K) + glucose (mmol/L) The effective osmo‐
lality (formula above) is frequently in the range of 300–350 mOsm/Kg.
6.2. Fluids and electrolytes
The objectives of fluid and electrolyte replacement therapy are [1]:
• Restoration of circulating volume
• Replacement of sodium and the ECF and intracellular fluid deficit of water
• Improved glomerular filtration with enhanced clearance of glucose and ketones from the
blood
• Reduction of risk of cerebral edema
6.3. Fluids
• Establish two I.V. lines: one for fluids and electrolytes and the other for insulin infusion
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• Shock with hemodynamic compromise is rare in pediatric DKA. If the patient is shocked,
administer shock therapy: 10 ml/Kg 0.9% normal saline (or Ringer's lactate or acetate)
through a large bore cannula, over 0.5 hr. Re-assess the patient and repeat up to a maxi‐
mum of 30 ml/kg if necessary, with reassessment after each bolus.
• The volume and rate of administration depends on circulatory status and, where it is clin‐
ically indicated.
• Calculate the Fluid Requirements
1. Deficit Fluid Requirements :
Patients with DKA have a deficit in extracellular fluid (ECF) volume that usually is in
the range 5–10%. Clinical estimates of the volume deficit are subjective and inaccurate,
therefore, in moderate DKA use 5–7%and in severe DKA 7–10% dehydration [4].
- Assess the degree of dehydration and calculate the deficit (% dehydration x body
weight) considering the age of the patient as shown in Table 1.
Degree of
Dehydration Infants & children <8 years Children "/>8 years
Degree Fluids Degree Fluids
Mild 5% 50 ml/kg 3% 30 ml/kg
Moderate 8% 80 ml/kg 5% 50 ml/kg
Severe 10% 100 ml/kg 8% 80 ml/kg
Table 1. Calculation of deficit fluid requirements in children presenting with DKA (1)
2. Maintenance Fluid Requirements:
Age (years) Amount of fluids
0-2 80 ml/kg/24hr
3-5 70 ml/kg/24hr
6—9 60 ml/kg/24hr
10-14 50 ml/kg/24hr
Adult ("/>15) 35 ml/kg/24hr
Table 2. Calculation of maintenance fluid requirements (1)
3. Total working fluid = deficit + maintenance (calculated for 48 hours)
• Type of fluids
Diabetic Ketoacidosis: Clinical Practice Guidelines
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- If blood glucose is over 300 mg/dl, start with isotonic saline, then when blood glucose goes
down to 250 mg/dl, add glucose 5% to isotonic saline in a 1:1 ratio if acidosis is corrected. If
acidosis is not corrected, add glucose 10% to isotonic saline in 1:1 ratio.
- In case of hyperosmolarity (> 340 mosm/kg), or if corrected Na is 155 mEq/l or more, use
half normal saline (0.45% ) instead of normal saline (0.9%), to prevent cerebral edema but
only after correction of shock and severe dehydration. It is advisable to use it after 6 hours
from initiation of fluid therapy.
Principles of Water and Salt Replacement and Reduction of Risk of Cerebral Edema
There is no convincing evidence of an association between the rate of fluid or sodium ad‐
ministration used in the treatment of DKA and the development of cerebral edema [26]. No
treatment strategy can be definitively recommended as being superior to based on evidence.
The principles described below were endorsed by a panel of expert physicians representing
the Lawson Wilkins Pediatric Endocrine Society (LWPES), the European Society for Paediat‐
ric Endocrinology (ESPE), and the International Society for Pediatric and Adolescent Diabe‐
tes (ISPAD) [4,5].
• Water and salt deficits must be replaced
• IV or oral fluids that may have been given in another facility before assessment should be
factored into calculation of deficit and repair
• In addition to clinical assessment of dehydration, calculation of effective osmolality may
be valuable to guide fluid and electrolyte therapy.
• Urinary losses should not routinely be added to the calculation of replacement fluid, but
may be necessary in rare circumstances.
• The use of large amounts of 0.9% saline has been associated with the development of hy‐
perchloremic metabolic acidosis [27].
6.4. Insulin therapy
Regardless of the type of diabetes, the child who presents with severe fasting hyperglyce‐
mia, metabolic derangements, and ketonemia will require insulin therapy to reverse the
metabolic abnormalities [2]
DKA is caused by a decrease in effective circulating insulin associated with increases in
counter-regulatory hormones {glucagon, catecholamines, growth hormone (GH), cortisol}.
Although rehydration alone causes some decrease in blood glucose concentration, insulin
therapy is essential to normalize blood glucose and suppress lipolysis and ketogenesis [1].
Extensive evidence indicates that ‘low dose’ IV insulin administration should be the standard
of care [4].
• Start insulin infusion 1–2 hours after starting fluid replacement therapy; i.e. after the pa‐
tient has received initial volume expansion [28].
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Correction of insulin deficiency
◦ Dose: 0.1 unit/kg/hour (for example, one method is to dilute 50 units regular [soluble]
insulin in 50 mL normal saline, 1 unit = 1 mL)
◦ Route of administration IV
◦ An IV bolus is unnecessary, may increase the risk of cerebral edema, and should not be
used at the start of therapy
• The dose of insulin should usually remain at 0.1unit/kg/hour at least until resolution of
DKA (pH >7.30, bicarbonate >15 mmol/L and/or closure of the anion gap), which invaria‐
bly takes longer than normalization of blood glucose concentrations.
• If the patient demonstrates marked sensitivity to insulin (e.g., some young children with
DKA, patients with HHS, and some older children with established diabetes), the dose
may be decreased to 0.05 unit/kg/hour, or less, provided that metabolic acidosis continues
to resolve.
• To prevent an unduly rapid decrease in plasma glucose concentration and hypoglycemia,
5% glucose should be added to the IV fluid (e.g., 5% glucose in 0.45% saline) when the
plasma glucose falls to approximately 250–300 mg/dL, or sooner if the rate of fall is pre‐
cipitous.
◦ It may be necessary to use 10% or even 12.5% dextrose to prevent hypoglycemia while
continuing to infuse insulin to correct the metabolic acidosis. The fall of blood glucose
should not exceed 100 mg per hour. If blood glucose drops more than 100 mg/hr, re‐
duce insulin infusion to 0.05 U/kg/hr. Aim to keep blood glucose at about 11 mmol/L
(200 mg/dL) until resolution of DKA
• If biochemical parameters of DKA (pH, anion gap) do not improve, reassess the patient,
review insulin therapy, and consider other possible causes of impaired response to insu‐
lin; e.g., infection, errors in insulin preparation.
• In circumstances where continuous IV administration is not possible, hourly or 2-hourly
subcutaneous (SC) or intramuscular (IM) administration of a short- or rapid-acting insulin
analog (insulin lispro or insulin aspart) is safe and may be as effective as IV regular insu‐
lin infusion, but should not be used in subjects whose peripheral circulation is impaired.
6.5. Potassium replacement
Pathophysiology of potassium depletion in DKA [4]
Children with DKA suffer total body potassium deficits of the order of 3 to 6 mmol/kg. The
major loss of potassium is from the intracellular pool.
Intracellular potassium is depleted because of the following factors:
• increased plasma osmolality drags water and potassium out of cells
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• glycogenolysis and proteolysis secondary to insulin deficiency cause potassium efflux
from cells
• Potassium is lost from the body from vomiting and as a consequence of osmotic diuresis.
• Volume depletion causes secondary hyperaldosteronism, which promotes urinary potas‐
sium excretion.
- Despite potassium depletion, at presentation, serum potassium levels may be normal, in‐
creased or decreased. Renal dysfunction, by enhancing hyperglycemia and reducing potassi‐
um excretion, contributes to hyperkalemia. Administration of insulin and the correction of
acidosis will drive potassium back into the cells, decreasing serum levels. The serum potas‐
sium concentration may decrease abruptly, predisposing the patient to cardiac arrhythmias.
Guidelines of Potassium supplementation [1]
• Replacement therapy is required regardless of the serum potassium concentration
• If the patient is hypokalemic, start potassium replacement at the time of initial volume ex‐
pansion and before starting insulin therapy. Otherwise, start replacing potassium after in‐
itial volume expansion and concurrent with starting insulin therapy.
• If the patient is hyperkalemic, postpone potassium replacement until the patient voids
urine
• If immediate serum potassium measurements are unavailable, an ECG may help to deter‐
mine whether the child has hyper- or hypokalemia. Flattening of the T wave, widening of
the QT interval, and the appearance of U waves indicate hypokalemia. Tall, peaked, sym‐
metrical, T waves and shortening of the QT interval are signs of hyperkalemia.
• The starting potassium concentration in the infusate should be 40 mmol/L or 20 mmol po‐
tassium/L in the patient receiving fluid at a rate >10 mL/kg/h. Subsequent potassium re‐
placement therapy should be based on serum potassium measurements.
• Potassium replacement should continue throughout IV fluid therapy. The maximum rec‐
ommended rate of intravenous potassium replacement is usually 0.5 mmol/kg/hr
• If hypokalemia persists despite a maximum rate of potassium replacement, reduce the
rate of insulin infusion
6.6. Phosphate
Phosphate is lost as a result of osmotic diuresis in DKA. Plasma phosphate levels fall after
starting treatment by insulin, which promotes entry of phosphate into cells.
Prospective studies have not shown clinical benefit from phosphate replacement. Severe hy‐
pophosphatemia in conjunction with unexplained weakness should be treated. Administra‐
tion of phosphate may induce hypocalcemia. Potassium phosphate salts may be safely used
as an alternative to or combined with potassium chloride or acetate, provided that careful
monitoring of serum calcium is performed to avoid hypocalcemia [2]
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6.7. Acidosis
Severe metabolic acidosis is hazardous leading to decreased myocardial performance, de‐
creased response of respiratory center, peripheral and cerebral vasodilatation and life threat‐
ening hyperkalemia. Nevertheless, it can be reversible by fluid and insulin replacement;
insulin stops further ketoacid production and allows ketoacids to be metabolized, which
generates bicarbonate. Treatment of hypovolemia improves tissue perfusion and renal func‐
tion, thereby increasing the excretion of organic acids[1].
Controlled trials have shown no clinical benefit from bicarbonate administration. Moreover,
bicarbonate therapy may be more hazardous than acidosis itself. It can cause paradoxical
CNS acidosis and promotes intracellular acidosis and cerebral edema. Moreover, rapid cor‐
rection of acidosis with bicarbonate causes hypokalemia, while sodium overload can result
in increasing osmolality. Late alkalemia can lead to shift of oxygen dissociation curve to the
left, with impaired O2 delivery to the tissues & increased anaerobic glycolysis[4].
Nevertheless, there may be selected patients who may benefit from cautious alkali thera‐
py[1]. These include: patients with severe acidemia (arterial pH <6.9) in whom decreased
cardiac contractility and peripheral vasodilatation can further impair tissue perfusion, and
patients with life-threatening hyperkalemia
• Bicarbonate administration is not recommended unless the acidosis is profound and like‐
ly to affect adversely the action of adrenaline/epinephrine during resuscitation.
• If bicarbonate is considered necessary, cautiously give 1–2 mmol/kg over 60 minutes.
6.8. Introduction of oral fluids and transition to SC insulin injections
• Oral fluids should be introduced only when the clinical condition has become stable,
however mild acidosis/ketosis may still be present.
• When oral fluid is tolerated, IV fluid should be reduced and change to SC insulin is plan‐
ned.
• To prevent rebound hyperglycemia the first SC injection should be given 15–30 minutes
(with rapid acting insulin) or 1–2 hours (with regular insulin) before stopping the insulin
infusion to allow sufficient time for the insulin to be absorbed. With intermediate- or
long-acting insulin, the overlap should be longer and the IV insulin gradually lowered.
For example, for patients on a basal-bolus insulin regimen, the first dose of basal insulin
may be administered in the evening and the insulin infusion is stopped the next morning.
• After transitioning to SC insulin, frequent blood glucose monitoring is required to avoid
marked hyperglycemia and hypoglycemia [2].
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7. Morbidity and mortality from DKA
The mortality rate from DKA in children is 0.15% to 0.30% [11,12]. Cerebral edema accounts
for 60% to 90% of all DKA deaths [13,14]. Ten % to 25% of survivors of cerebral edema have
significant residual morbidity [29]
Other rare causes of morbidity and mortality include:
• Hypokalemia
• Hyperkalemia
• Severe hypophosphatemia
• Hypoglycemia
• Other central nervous system complications (disseminated intravascular coagulation, du‐
ral sinus thrombosis, basilar artery thrombosis)
• Peripheral venous thrombosis
• Sepsis
• Rhinocerebral or pulmonary mucormycosis
• Aspiration pneumonia
• Pulmonary edema
• Adult respiratory distress syndrome (ARDS)
• Pneumothorax, pneumomediastinum and subcutaneous emphysema
• Rhabdomyolysis
• Acute renal failure
• Acute pancreatitis [30]
7.1. Cerebral edema
Cerebral edema is responsible for the majority of deaths related to DKA in children, and sig‐
nificant neurologic morbidity persists in many of the survivors. The incidence of cerebral
edema in national population studies is 0.5–0.9% and the mortality rate is 21–24%.The
pathogenesis of both its initiation and progression is unclear and incompletely understood,
although a number of mechanisms have been proposed. These include cerebral ischemia
and hypoxia, fluid shifts caused by inequalities in osmolarity between the extravascular and
intravascular intracranial compartments, increased cerebral blood flow, and altered mem‐
brane ion transport. Demographic factors that have been associated with an increased risk of
cerebral edema include [13,14,29]:
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Epidemiological factors
• Newly diagnosed cases
• Young age: < 5 years old
• Longer duration of symptoms
• Prolonged illness
• Extended history of poor metabolic control
Features at presentation
• Severe acidosis (initial pH < 7.1)
• Greater hypocapnia after adjusting for degree of acidosis
• High Blood urea nitrogen
• Severe dehydration
• Abnormal mental status
Therapeutic interventions
• Rapid rehydration (> 50cc/ kg in first 4 hrs)
• Bicarbonate therapy for correction of acidosis
• Insulin administration in the first hour of therapy
Changes in biochemical values during treatment
• Severe Hypernatremia
• Persistent hyponatremia
• An attenuated rise in measured serum sodium concentrations during therapy
• Non closure of the anion gap
Warning signs and symptoms of cerebral edema include:
• Headache & slowing of heart rate
• Change in neurological status (restlessness, irritability, increased drowsiness, inconti‐
nence)
• Specific neurological signs (e.g., cranial nerve palsies)
• Rising blood pressure
• Decreased oxygen saturation
Clinically significant cerebral edema usually develops 4–12 hours after treatment has start‐
ed, but can occur before treatment has begun or, rarely, may develop as late as 24–48 hours
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after the start of treatment. Symptoms and signs are variable. A method of clinical diagnosis
based on bedside evaluation of neurological state is shown below [23]:
7.2. Diagnostic criteria
• Abnormal motor or verbal response to pain
• Decorticate or decerebrate posture
• Cranial nerve palsy (especially III, IV, and VI)
• Abnormal neurogenic respiratory pattern (e.g., grunting, tachypnea, Cheyne-Stokes respi‐
ration, apneusis)
7.2.1. Major criteria
• Altered mentation/fluctuating level of consciousness
• Sustained heart rate deceleration (decrease more than 20 beats per minute) not attributa‐
ble to improved intravascular volume or sleep state
• Age-inappropriate incontinence
7.2.2. Minor criteria
• Vomiting
• Headache
• Lethargy or not easily arousable
• Diastolic blood pressure >90 mm Hg
• Age <5 years
One diagnostic criterion, two major criteria, or one major and two minor criteria have a sen‐
sitivity of 92% and a false positive rate of only 4%.
A chart with the reference ranges for blood pressure and heart rate, which vary depending
on height, weight, and gender, should be readily available, either in the patient's chart or at
the bedside.
8. Treatment of cerebral edema [1,2,4]
• Start as early as you suspect the condition, do not delay treatment until radiographic evi‐
dence
• Transfer to the ICU (if not already there)
• Restrict IV fluids to 2/3 maintenance and replace deficit over 72 hr rather than 24 hr
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• Give mannitol 0.5-1 g/kg IV (2.5 ml/kg of 20% solution) over 20 minutes and repeat after 6
hours, if there is no initial response in 30 minutes to 2 hours
• Hypertonic saline (3%), 5-10 mL/kg over 30 minutes, may be an alternative to mannitol or
a second line of therapy if there is no initial response to mannitol
• Elevate the head of the bed
• Intubation may be necessary for the patient with impending respiratory failure, but ag‐
gressive hyperventilation (to a pCO2 <2.9 kPa [22 mm Hg]) has been associated with poor
outcome and is not recommended.
• After treatment for cerebral edema has been started, a cranial CT scan should be obtained
to rule out other possible intracerebral causes of neurologic deterioration (10% of cases),
especially thrombosis or hemorrhage, which may benefit from specific therapy.
9. Prevention of recurrent DKA
Home measurement of blood ß –OHB concentrations, when compared to urine ketone test‐
ing, decreases diabetes-related hospital visits (both emergency department visits and hospi‐
talizations) by the early identification and treatment of ketosis. Blood ß -OHB measurements
may be especially valuable to prevent DKA in patients who use a pump because interrupted
insulin delivery rapidly leads to ketosis. There may be dissociation between urine ketone
(sodium nitroprusside only measures acetoacetate and acetone) and serum ß -OHB concen‐
trations, which may be increased to levels consistent with DKA when a urine ketone test is
negative or shows only trace or small ketonuria [4].
A psychiatric social worker or clinical psychologist should be consulted to identify the psy‐
chosocial reason(s) contributing to development of DKA. Insulin omission can be prevented
by schemes that provide education, psychosocial evaluation and treatment combined with
adult supervision of insulin administration. Diabetes education of the child and his/her fam‐
ily is the cornerstone to prevent DKA occurrence and recurrence.
10. Conclusion
10.1. Future thoughts and recommendations
1. DKA is the first presentation of ~25% of young diabetics. Cerebral edema is a major risk
causing mortality and morbidity.
2. The child is not a miniature adult. Children and adolescents with DKA should be man‐
aged in centers experienced in treatment and monitoring of DKA.
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3. Successful management of DKA requires meticulous monitoring of the patient’s clinical
and biochemical response to treatment so that timely adjustments in treatment can be
made when indicated by the patient’s clinical or laboratory data
4. Fluid administration should rehydrate evenly over 48 hours at a rate rarely in excess of
1.5–2 times the usual daily maintenance requirement.
5. Begin insulin infusion with 0.1 U/kg/h. 1–2 hours after starting fluid replacement thera‐
py. Increase the amount of glucose administered if blood glucose is falling too rapidly
or acidosis is not resolving.
6. Even with normal or high levels of serum potassium at presentation, there is always a
total body deficit of potassium. Begin with 40 mmol potassium/L in the infusate or 20
mmol potassium/L in the patient receiving fluid at a rate >10 mL/kg/h.
7. There is no evidence that bicarbonate is either necessary or safe in DKA. It is used cau‐
tiously in severe acidemia (arterial pH <6.9) and in life-threatening hyperkalemia
8. Despite much effort to identify the cause of cerebral edema, its pathogenesis is incom‐
pletely understood. Further research is needed in this area.
9. In case of profound neurological symptoms, Mannitol should be given immediately.
10. All cases of recurrent DKA are preventable
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